BiotechPulse | Healthcare Insights

top of page

HEALTHCARE INSIGHTS

BiotechPulse

HEALTHCARE INSIGHTS

Stay ahead of the curve
with curated research & insights.

Subscribe to our free newsletter, Quicktakes.

Read Our Reports

Our Latest Articles

The FDA's Flexibility Problem: When Rigor Becomes Risk

Sophie Johnston

Apr 285 min read

Balancing Regulatory Standards with the Need for Rare Disease Innovation

Balancing Regulatory Standards with the Need for Rare Disease Innovation

Lilly's $6.3B Neuro Bet Isn't on a Drug, It's on a Biological Switch

Sophie Johnston

Apr 96 min read

Why Eli Lilly paid a massive premium for Centessa's narcolepsy platform and what it signals for the future of neuro-biotech M&A.

Why Eli Lilly paid a massive premium for Centessa's narcolepsy platform and what it signals for the future of neuro-biotech M&A.

Anatomy of a $6.7 Billion Deal: Why TERN-701 Was Merck's Must-Have Asset

Apr 15 min read

Anatomy of a $6.7 Billion Deal: Why TERN-701 Was Merck's Must-Have Asset

Anatomy of a $6.7 Billion Deal: Why TERN-701 Was Merck's Must-Have Asset

© 2025 by BiotechPulse

Quicktakes

Subscribe to our free newsletter to get our latest coverage right in your inbox.

Startups

Venture Capital

Read Our Reports

bottom of page